Polyp Burden Drops With Sulindac/Erlotinib Combo in FAP
Patients with familial adenomatous polyposis have an increased risk for colorectal polyps and cancer; however, treatment with a combination of sulindac and erlotinib reduced their colorectal polyp burden by more than two thirds. (Source: CancerNetwork)
Source: CancerNetwork - February 15, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer Genetic Disorders News Source Type: news
ECC 2015: GIOTRIF ® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Erlotinib Overdose Tied to Conjunctivitis
Findings in case study of man being treated for non - small - cell lung cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 17, 2017 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Emergency Medicine, Oncology, Ophthalmology, Pharmacy, Journal, Source Type: news
Combination treatment targeting glucose in advanced brain cancer shows promising results in preclinical study
UCLA HealthPositron emission tomography images show glioblastoma tumor glucose uptake before, left, and after treatment in mice.FINDINGSUCLA scientists have discovered a potential combination treatment for glioblastoma, the deadliest form of brain cancer in adults. The three-year study led by David Nathanson, a member of UCLA ’s Jonsson Comprehensive Cancer Center, found that the drug combination tested in mice disrupts and exploits glucose intake, essentially cutting off the tumor’s nutrients and energy supply. This treatment then stimulates cell death pathways — which control the cancer cells’ fate — and prev e...
Source: UCLA Newsroom: Health Sciences - October 9, 2017 Category: Universities & Medical Training Source Type: news
How CD44s gives brain cancer a survival advantage
(Baylor College of Medicine) In the case of glioblastoma multiforme, the deadliest type of brain cancer, researchers have discovered that the molecule CD44s seems to give cancer cells a survival advantage. In the lab, eliminating this advantage by reducing the amount of CD44s resulted in cancer cells being more sensitive to the deadly effects of the drug erlotinib. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 18, 2017 Category: Cancer & Oncology Source Type: news
Cabozantinib Improves Outcomes Over Erlotinib in Advanced NSCLC
Cabozantinib alone or in combination with erlotinib improved survival outcomes among patients with advanced EGFR wild-type non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 23, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news
Blood pressure drug may boost effectiveness of lung cancer treatment
A blood pressure drug may make a type of lung cancer treatment more effective, suggests a new study. Almost 2 million people are diagnosed with lung cancer every year worldwide and it is the top international cancer killer. The team studied a lung cancer drug called erlotinib which can be used to treat between 10 and 30 per cent of lung cancer patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 27, 2016 Category: Science Source Type: news
Trial Shows Interactions Between KRAS Mutations, Erlotinib Therapy in NSCLC
A trial showed that KRAS wild-type NSCLC patients fare better with regimens containing erlotinib, while KRAS-mutated patients had better outcomes without erlotinib. (Source: CancerNetwork)
Source: CancerNetwork - August 1, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news
Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif < sup > ® < /sup > (afatinib) compared to Tarceva < sup > ® < /sup > (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
ECC 2015: GIOTRIF < sup > ® < /sup > (afatinib) demonstrates superior survival compared to Tarceva < sup > ® < /sup > (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Afatinib vs Erlotinib head-to-head trial results
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
ASCO 2015: Superior OS for afatinib vs erlotinib
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Tarceva (Erlotinib) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 13, 2016 Category: Drugs & Pharmacology Source Type: news
June 6, 2016: Pharmaceutical Companies To Pay $67 Million To Resolve False Claims Act Allegations Relating To Tarceva
(Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - June 8, 2016 Category: Medical Law Source Type: news
